# Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

> **NCT04346628** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 149 (actual)

## Conditions studied

- Sars-CoV2
- COVID-19

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Placebo
- **OTHER:** Standard of care treatment

## Key facts

- **NCT ID:** NCT04346628
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-12
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-16
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346628, "Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04346628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*